The Saint Vincent Hospital’s Structural and Valvular Heart Disease Program now offers Transcatheter Mitral Valve Replacement (TMVR). This is a non-surgical approach for patients with significant mitral stenosis and/or regurgitation involving a prior surgical implant of a bioprosthetic mitral valve who are high risk for a reoperation.
Saint Vincent Hospital is utilizing the Edwards SAPIEN 3 valve for the TMVR procedure. The TMVR provides a new treatment option for patients with a deteriorating mitral valve who are at high risk for subsequent open heart surgery to replace their bioprosthetic valve. The SAPIEN 3 valve is the only transcatheter valve approved for valve-in-valve procedures.
“I am very proud to be part of the team bringing this exciting technology to Saint Vincent Hospital,” said Dr. Joseph Hannan, Co-Director of the Structural and Valvular Heart Disease program and Director of Interventional Cardiology at Saint Vincent Hospital. “Our cardiac program continues to make major advances in providing innovative cardiac care to the people of Central Massachusetts.”
“I believe the Edwards SAPIEN 3 transcatheter heart valve for mitral valve replacement inside a failed surgical valve replacement is a great technological breakthrough in the modern medical era,” added Dr. Robert Bojar, Chief of Cardiac Surgery at Saint Vincent Hospital. “I am thrilled that we are now able to offer this service to our patients.”
“Heart disease is the #1 cause of death in the United States, killing more people every year than all forms of cancer combined,” said Jeffrey M .Welch, chief executive officer at Saint Vincent Hospital. “Our goal is to bring new medical advances to our community, including transcatheter aortic valve replacement and transcatheter mitral valve repair and replacement, which could offer better outcomes for some of our most high-risk patients.”
The Edwards SAPIEN 3 valve was approved by the FDA in 2015 for severe, symptomatic aortic stenosis patients at high risk for open-heart surgery, and, in 2016, received approval for the treatment of patients with aortic stenosis who are at intermediate risk for open-heart surgery. In 2017, the FDA approved treatment of a deteriorating bioprosthetic valve in the mitral position with the SAPIEN 3 valve. The SAPIEN 3 valve builds on Edwards’ decades of experience in the development of tissue heart valves. For more information about the all cardiac services offered at Saint Vincent Hospital, visit https://www.stvincenthospital.com/our-services/heart-and-vascular-care.